K Peden

Summary

Affiliation: Food and Drug Administration
Country: USA

Publications

  1. ncbi request reprint Biological activity of residual cell-substrate DNA
    K Peden
    Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892, USA
    Dev Biol (Basel) 123:45-53; discussion 55-73. 2006
  2. pmc Changes in both gp120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1
    K Fujita
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892
    J Virol 66:4445-51. 1992
  3. doi request reprint WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007
    I Knezevic
    World Health Organization, Department of Immunization, Vaccines and Biologicals, Quality, Safety and Standards Team, Avenue Appia, CH 1211 Geneva, Switzerland
    Biologicals 36:203-11. 2008

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Biological activity of residual cell-substrate DNA
    K Peden
    Division of Viral Products, OVRR, CBER, FDA, Bethesda, MD 20892, USA
    Dev Biol (Basel) 123:45-53; discussion 55-73. 2006
    ..In this paper, we discuss our approaches to address this issue and describe some preliminary work...
  2. pmc Changes in both gp120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1
    K Fujita
    Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892
    J Virol 66:4445-51. 1992
    ..They also may have important implications for the generation of viruses with increased growth potential and expanded host range seen in the late stages of HIV disease...
  3. doi request reprint WHO Study Group on cell substrates for production of biologicals, Geneva, Switzerland, 11-12 June 2007
    I Knezevic
    World Health Organization, Department of Immunization, Vaccines and Biologicals, Quality, Safety and Standards Team, Avenue Appia, CH 1211 Geneva, Switzerland
    Biologicals 36:203-11. 2008
    ..The Study Group is working on the preparation of a revised WHO document, and a broad consultation with regulators, manufacturers, and other relevant parties is planned for 2008...